Introduction The Canadian Genito-Urinary Research Consortium conducted a consensus development conference leading to 31 recommendations. We conducted a survey comparing community-based practice with the consensus recommendations on the management of metastatic castration sensitive prostate cancer (mCSPC), metastatic castration resistant prostate cancer (mCRPC) and non-metastatic castration resistant prostate cancer (nmCRPC). Methods An 87-item online questionnaire was sent to 600 community urologists and oncologists involved in the treatment of prostate cancer. Results Based on the 72 responses received, a discordance of >25% was observed in 15 recommendations (48%). Of the academic physicians, 89% indicated treating with agents approved for non-metastatic castration resistant prostate cancer compared to 50% of community physicians (p=0.0005). Discrepancies were also observed for radiation to the prostate for low-volume metastatic castration sensitive prostate cancer which was 74% (academic) vs 27% (community), (p<0.0001); criteria for stopping therapy in metastatic castration sensitive prostate cancer in which 78% of academic physicians favored continuation of therapy in the event of PSA progression only, compared to 24% of community physicians. Sequencing of therapy after prior apalutamide for non-metastatic castration resistant prostate cancer using subsequent docetaxel treatment was observed in 81% of academic physicians vs 35% of community physicians, (p<0.0001), and use of genetic testing was favored by 74% of academics vs 36% of community physicians, (p<0.0001) for newly diagnosed metastatic prostate cancer. Conclusions The areas of discordance between a national sample of community-based physicians and academic consensus recommendations represent potential areas for education, practice tools and future research.